Keyword Analysis & Research: relypsa
Keyword Research: People who searched relypsa also searched
Search Results related to relypsa on Search Engine
-
CSL Vifor US | Home
https://www.cslvifor.us/
WEBCSL Vifor aims to be the global leader in iron deficiency and nephrology. We strive to help patients with severe and chronic disease lead better, healthier lives. CSL Vifor US is a biopharmaceutical leader driven by its promise to save and improve lives. We manufacture remedies for rare and serious conditions.
DA: 85 PA: 27 MOZ Rank: 17
-
Swiss group Galencia buys US biotech Relypsa for $1.5 billion
https://www.biopharmadive.com/news/swiss-group-galencia-buys-us-biotech-relypsa-for-15-billion/423055/
WEBJul 21, 2016 · Dive Brief: Swiss healthcare group Galencia will pay $1.53 billion to acquire the U.S. biotech Relypsa, maker of a recently approved drug for hyperkalemia, the companies announced Thursday. Galencia owns a major pharmacy network in Switzerland in addition to Vifor Pharma, a specialty drugmaker which had sought to expand its market presence in ...
DA: 99 PA: 68 MOZ Rank: 19
-
Relypsa Announces FDA Approval of Veltassa | HFSA
https://hfsa.org/relypsa-announces-fda-approval-veltassa
WEBRelypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved VeltassaTM (patiromer) for oral suspension, a new polymer medicine that binds potassium, for the treatment of hyperkalemia.
DA: 46 PA: 1 MOZ Rank: 45
-
Galenica snaps up Relypsa and its Veltassa med for $1.53B in march
https://www.fiercepharma.com/pharma/galenica-snaps-up-relypsa-and-its-veltassa-med-for-1-53b-march-toward-vifor-spinoff
WEBJul 21, 2016 · Swiss-based Galenica will pay $32 per share for Relypsa, gaining a U.S. commercial organization as well as full rights to Veltassa, which treats high potassium levels in patients with chronic ...
DA: 43 PA: 33 MOZ Rank: 15
-
After ZS Pharma buyout, Relypsa slated to be next on the hit list
https://www.fiercebiotech.com/biotech/after-zs-pharma-buyout-relypsa-slated-to-be-next-on-hit-list
WEBApr 8, 2016 · biotech deals Relypsa. As hype around new treatments for the blood disorder hyperkalemia continues unabated after AstraZeneca's $2.7 billion buyout of ZS Pharma last year, Relypsa ($RLYP),...
DA: 15 PA: 39 MOZ Rank: 34
